Molina Healthcare, Inc. (MOH) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Molina Healthcare, Inc. provides managed healthcare services primarily under Medicaid, Medicare, and Marketplace programs. As of the reporting date, the company served approximately 5.0 million members across 21 states. The company operates four reportable segments: Medicaid, Medicare, Marketplace, and Other.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $10,796 million | $11,147 million |
| Premium Revenue | $10,172 million | $10,628 million |
| Operating Income | $83 million | $433 million |
| Net Income | $14 million | $298 million |
| Diluted EPS | $0.27 | $5.45 |
| Medical Care Ratio (MCR) | 91.1% | 89.2% |
| Operating Cash Flow | $1,082 million | $190 million |
| Cash & Investments | $9,251 million | $8,256 million |
| Long-Term Debt | $3,767 million | $3,766 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3.1% year-over-year, driven by a 4.3% drop in premium revenue. This was primarily due to a 12% decrease in membership (down 718,000 members), attributed to general Medicaid market contraction, the expiration of the Virginia Medicaid contract, and a strategic reduction in Marketplace membership.
- Profitability Compression: Operating income fell 80.8% to $83 million. Net income dropped 95.3% to $14 million. The decline was significantly impacted by a $93 million impairment charge related to intangible assets for the Medicare Advantage-Part D (MAPD) product, which the company plans to exit in 2027.
- Margin Pressure: The consolidated Medical Care Ratio (MCR) increased to 91.1% from 89.2%, reflecting higher utilization and medical costs across all segments. The General and Administrative (G&A) ratio also rose slightly to 7.2% from 6.9%.
- Cash Flow Strength: Despite lower net income, operating cash flow surged to $1.082 billion (from $190 million in Q1 2025), largely due to favorable timing in government receivable settlements and changes in working capital.
Guidance, Outlook, and Risks
- Strategic Shift: Management confirmed a strategic pivot to focus exclusively on dual-eligible members in Medicare, leading to the planned exit of the MAPD product in 2027. This resulted in the $93 million impairment charge.
- Membership Outlook:
- Medicaid: Enrollment is expected to decrease to 4.5 million by year-end 2026 due to market contraction.
- Marketplace: Enrollment is projected to decrease to approximately 250,000 members by year-end 2026 as part of a pricing strategy to restore target margins.
- Medicare: Enrollment is expected to decrease by approximately 12% to 230,000 members by year-end 2026.
- Legislative Risks: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces work requirements and cost-sharing for Medicaid Expansion, potentially reducing enrollment by 15-20% by 2029. It also limits provider tax revenues and Marketplace subsidies.
- Legal Proceedings: The company is facing a putative securities class action (Hindlemann v. Molina Healthcare, Inc.) and a shareholder derivative suit regarding disclosures and earnings guidance. No loss estimate can be provided at this time.
- Credit Rating: Standard & Poor's downgraded the company's senior notes to "BB-" from "BB" in April 2026, which may impact borrowing costs.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used for the $93 million MAPD impairment and the timeline for the 2027 exit.
- Membership Attrition: Monitor the rate of Medicaid and Marketplace member loss against the projected year-end targets of 4.5 million and 250,000, respectively.
- Legislative Impact: Assess the actual implementation timeline of the OBBBA work requirements and provider tax limitations by state.
- Legal Exposure: Track developments in the Hindlemann securities class action and derivative suit for potential financial impact.
- Credit Covenants: Confirm continued compliance with the amended Interest Coverage Ratio (temporarily reduced to 1.75:1.00 for Q1 2026) under the Credit Agreement.